"To specifically overcome resistance to hormone treatment that's sort of a paradigm change, " said Gabriel Hortobagyi, head of breast oncology at MD Anderson Cancer Center in Houston and lead author of Bolero-2.

WSJ: Breast-Cancer Drugs Raise Hopes